Catapult open for business with £1M investment in cutting-edge lab capacity to support UK drug discovery
World-class technology and expertise are now available to UK drug discovery companies as a result of new laboratory facilities developed by the Medicines Discovery Catapult and launched today (Wednesday 29th March) at the University of Warwick.
The Catapult’s investment in solid-state NMR will provide technology previously been unavailable in the UK. In addition, advanced mass spectrometry and liquid handling in the facility will support advanced screening and target validation to identify future therapies for complex diseases.
One initial focus of the work being undertaken on site will be on the increasing threat of anti-microbial resistance (AMR).
These new facilities and expert post-doctoral staff will enable biotechs, CROs and academic collaborators to work at Warwick to develop complex assays and monitor molecules, drug targets and proteins in unique detail.
The facility, established in close collaboration with the University, also offers excellent access to the wider UK academic community and its resources.
The site at Warwick has been developed alongside facilities at the Catapult’s headquarters site in Alderley Park, Cheshire.
They will both drive innovative, fast-to-patient drug discovery supporting collaborations between industry, academic teams and medical research charities, and will help drive UK health and wealth in line with the government’s Life Sciences strategy.
Today’s announcement has been welcomed by the Biotech Industry Association (BIA), the Association of British Pharmaceutical Industry (ABPI) and Association of Medical Research Charities (AMRC).
Former Health Minister The Rt. Hon. The Lord Warner officially opened the facility in front of an audience of biotech businesses, academics and stakeholders from the life sciences community.
“I am delighted that this facility, with its staff and unique equipment, enables innovative, applied research to be undertaken by the drug discovery community here in the UK.
The UK life sciences community is a vital part of the UK’s future health and wealth and I am delighted to be supporting this important work.”
Chris Molloy, CEO of the Medicines Discovery Catapult, said,
“The Catapult is here to help the UK drug discovery industry remain successful in a highly competitive world. This facility, its people and its first-in-UK technology is just one step of many in that journey.
“Siting the laboratory here in Warwick was a natural choice. Warwick is an inventive and collaborative organisation with key centres of AMR and NMR research.
It is the right place to build a waterhole around which the community will gather to work together and solve the problems that no one group can solve alone.”
Chris Dowson, Professor of Microbiology at the University of Warwick, welcomed the addition of the Medicines Discovery Catapult to the University. He said,
“This Catapult laboratory has an extraordinary amount of capability in a small space, enabling us to make great advances in microbiology, chemistry and structural biology.
“We are already able to synthesise key reagents that allow new first in class assays to identify high value drug targets. The equipment which the Medicines Discovery Catapult has added allows us to keep going and do work that is more complex and sophisticated, and which nobody has been able to do previously. The potential is only limited by our imagination.
“In addition, we are keen to bring in SMEs as partners, providing research capabilities and equipment to use the laboratory as a portal between industry and academia.
The Catapult is providing this gateway, removing the usual barriers to engagement, enabling collaboration and providing a fantastic resource for the sector.”
Ian Campbell, Innovate UK’s Director of Health and Life Sciences, said:
“This new facility is a vital component in the early establishment of the Medicine Discovery Catapult. Antimicrobial resistance (AMR) is complex and this state-of-the-art laboratory will aid our understanding and accelerate the research and development of potential therapeutics. In addition, the range of equipment and expertise will open up significant opportunities for businesses to develop market-leading solutions.”
31st March 2017